Pharma Tech

EyePoint halves workforce and ends Phase III trial early after endpoint miss

Oct 20, 2026, 10:37 AM

Read Full Article → EyePoint halves workforce and ends Phase III trial early after endpoint miss

Translate article text

Choose a language and wait for the translated text.

The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.